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Abstract 
 
Prostaglandin E2 (PGE2) is responsible for inflammatory symptoms. However, PGE2 also 
suppresses pro-inflammatory cytokine production. There are at least 4 subtypes of PGE2 
receptors, EP1 – EP4, but it is unclear which of these specifically control cytokine production. 
The aim of this study was to determine which of the different receptors, EP1R - EP4R modulate 
production of tumor necrosis factor-α (TNF-α) in human monocytic cells. 
Human blood, or the human monocytic cell line THP-1 were stimulated with LPS. The actions 
of PGE2, alongside both selective agonists of EP1 – EP4 receptors, were assessed on LPS-
induced TNF-α release. The expression profiles of EP2R and EP4R in monocytes and THP-1 
cells were characterised by RT-qPCR. In addition, the production of TNF-α protein was 
evaluated following knockdown of the receptors using siRNA and over-expression of the 
receptors by transfection with constructs. 
PGE2 and also EP2 and EP4 agonists (but not EP1 or EP3 agonists) suppressed TNF-α 
production in blood and THP-1 cells.  LPS also up regulate expression of EP2R and EP4R but 
not EP1 or EP3.  siRNA for either EP2R or EP4R reversed the suppressive actions of PGE2 on 
cytokine production and  overexpression of EP2R and EP4R enhanced the suppressive actions 
of PGE2. 
This indicates that PGE2 suppression of TNF-α by human monocytic cells occurs via EP2R and 
EP4R expression. However EP4Rs also control their own expression and that of EP2 whereas 
the EP2R does not affect EP4R expression. This implies that EP4 receptors have an important 
master role in controlling inflammatory responses. 
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INTRODUCTION 
 
PGE2 is a major mediator present at sites of inflammation [1].  It is well established that PGE2 
contributes to the localised and systemic symptoms of inflammation. A key study by Portanova 
et al. [2] demonstrated that anti-PGE2 antibodies were able to reverse the swelling and pain in 
localized inflammation. This directly connects PGE2 to the development of inflammatory 
symptoms. The major pro-inflammatory cytokines tumor necrosis factor- (TNF-) and 
interleukin-1 (IL-1), which are produced in response to inflammatory stimuli such as 
lipopolysaccharide, sequentially induce PGE2 biosynthesis from macrophages in a concentration-
dependent manner [3]. However, other early studies also showed that exogenous PGE2 potently 
suppressed the production of TNF-from monocytic cells (at the transcriptional level) and the 
suppression of endogenous PGE2 production (using cyclooxygenase inhibitors) enhanced TNF-
synthesis clearly indicated that the downstream release of PGE2 is a negative-feedback loop [4, 
5]. It is now recognised that prostaglandins in general, and PGE2 in particular, play a 
cytoprotective and  controlling role in limiting immune and inflammatory activation and 
consequent pathology [6]. Thus, the suppressive action of PGE2 on TNF- production is an 
important axis in limiting the extent of an inflammatory response. The actions of PGE2 are 
mediated via at least 4 membrane receptors termed EP1 – EP4, each with it’s particular 
signalling system some of which overlap [6]. Suppression of TNF- production in monocytic 
cells can occur via EP2 receptors on the basis of a variety of agonists and antagonists of the 
respective receptors [1].  In the study of Brown et al. [1] it was also shown that the inhibition of 
TNF-production by PGE2 could be reversed to an extent by an EP4 receptor antagonist. 
However, it is very clear that these compounds have greatly overlapping activities with relatively 
poor selectivity between EP receptor subtypes, particularly to distinguish clearly between EP2 
and EP4 receptors.  Thus, an alternative approach is required to attempt to delineate which 
precise EP receptors are involved in controlling monocyte-derived cytokine production, 
particularly TNF-. 
 
Little information is available regarding the expression of the different EP receptor subtypes on 
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human monocyic cells, particularly those that are involved in downregulating cytokine 
production.  The receptors are controlled by the respective genes for each receptor i.e. PTGER1 – 
PTGER4  for EP1 – EP4 receptors respectively.  This study attempts to correlate the functional 
characteristics of suppressing LPS-induced TNF- production in monocytes by various PGE2 
analogues (agonists) to the expression of PTGER genes particularly PTGER2 and PTGER4.  
 
This study reports that PGE2 can control the expression of EP2 and EP4 receptors and that EP4-
selective agonists mimic this response whereas EP2 agonists are unable to do so. Coupled with 
the observation that overexpression of EP4 receptors enhances PGE2 suppression of TNF- 
production and siRNA silencing of EP4 receptor expression elevates TNF- and IL-1 
production but not the production of the anti-inflammatory cytokine IL-10, this implies that the 
regulation of EP receptor expression in monocytes occurs primarily via EP4 receptors and that 
they may be important controllers of inflammatory responses. In addition, it also indicates that 
gene expression of the receptors has direct functional consequences indicating a complex 
dynamic control during inflammatory responses.  
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MATERIALS AND METHODS  
Cell culture 
 
Preparation of THP-1 cells 
 
THP-1 cells were incubated in flasks containing RPMI 1640 with 10% (v/v) fetal calf serum 
(FCS) at 37°C, 100% humidity, 5% (v/v) CO2. Cells were passaged when they reached 80-90% 
confluence then collected for experiments by transferring them into 30ml sterile tubes followed 
by centrifugation at 400 x g for 5 minutes. The supernatant was discarded and RPMI 1640 was 
added to resuspend the cells. THP-1 cells were used at a concentration of 1 × 106 cells/ml. Cells 
were maintained at 37°C, 5% CO2. 
 
Human blood incubation protocol 
 
Whole human blood (700μl) was added to sterile 1 ml microcentrifuge tubes. To each 
microcentrifuge tube, different compounds were added in a volume of 100 µl to yield the various 
concentrations indicated in the results section. The incubations were all carried out in a final total 
volume of 1 ml. The samples were then gently vortex mixed and placed in an incubator for 22 
hours at 37°C, 100% humidity, 5% CO2 with the tubes remaining opened to allow CO2 access. 
Following incubation, the sample tubes were centrifuged at 12,000 x g for 40 seconds after 
which the plasma was transferred into fresh microcentrifuge tubes and stored at -20°C until 
required for the assay.  
 
THP-1 cells incubation protocol 
THP-1 cells (1x106 cells/ml) were added into 24-well or 6-well culture plates. Different 
treatments such as LPS, PGE2 etc., were always added in a volume of 50 µl (in order to yield the 
appropriate final concentrations indicated in the results section) in a final volume of 0.5 ml in 
each well of 24-well plates. In the 6-well plates, additions were adjusted to 200 µl in a final 
volume of 2 ml. The plates were then incubated at 37°C, 100 % humidity, 5% CO2 for 22 hours. 
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Following incubation, all samples were transferred into microcentrifuge tubes and stored at -
20°C until required for the assay. 
 
Measurement of cytokines 
The production of TNF-α, IL-1 and IL-10 was measured by sandwich ELISA assay as 
described previously [1].  
 
Statistical analysis of ELISA data 
All data was analysed statistically using Statview software (SAS Institute, North Carolina, USA). 
Levels of analytes were calculated from standard curves using 3rd order polynomial regression 
analysis. IC50 values for the inhibition of cytokine production were obtained using GraphPad 
Prism Version 5.0 (GraphPad Software Inc., California, USA). ANOVA tests (Fishers PLSD) 
were used to ascertain statistically significant changes in responses, with P < 0.05 regarded as a 
significant change. 
 
Transient cell transfection 
THP-1 cells were transfected with either siRNA duplexes from a PTGER4 TriFECTa RNAi kit 
(Integrated DNA technologies, Leuven, Belgium) for the knock-down study or Flag-PTGER4 
plasmid for the overexpression study. The nucleotide sequences for PTGER4 and negative 
control siRNA duplexes are shown in Table  1. THP-1 cells (1x106 cells/ml) were placed into 6-
well plates and incubated with different treatment in a final volume of 2 ml with either 5 μl of 
100nM siRNA duplexes  for knock-down assays or 5 μl of FLAG-PTGER4 plasmid (1904 ng/μl) 
for overexpression assays in the presence of 3 μl of transfection reagent (HiPerFect; Qiagen, 
UK)). Untransfected cells were used as controls. Also, in knock-down experiments, two negative 
control duplex siRNA (NC1, NC5) and a positive control were used. In overexpression 
experiments, an empty expression vector that did not contain a PTGER4 insert was prepared and 
used as a control. Plates were incubated at 37°C, 100 % humidity, 5% CO2 for different time 
points (3h-48h). Primary optimisation experiments were performed using different 
concentrations of all three siRNA duplexes (1nM, 10nM and 100nM), FLAG-PTGER4 (1904 
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ng/μl, 952 ng/μl and 476 ng/μl) and empty vector (2461 ng/μl, 1230 ng/μl and 615 ng/μl). 
 
 
 
 
 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tale 1. Nucleotide sequences of siRNA duplexes used for transfection of THP-1 cells 
 
Duplex 
No. 
 
Sequence 
 
 
PTGER
4Duplex 
1 
Forward 5'-
rGrCrArGrUrUrGrUrArCrCrArArGrUrGrArArArUrUrArUTT-3'  
Reverse  5'-
rArArArUrArArUrUrUrCrArCrUrUrGrGrUrArCrArArCrUrGrCrUrU-3'        
PTGER
4Duplex 
2  
Forward 5'-
rArGrUrGrCrUrCrArGrUrArArArGrCrArArUrArGrArGrAAG-3' 
Reverse  5'-
rCrUrUrCrUrCrUrArUrUrGrCrUrUrUrArCrUrGrArGrCrArCrUrGrU-3'     
PTGER
4Duplex 
3  
Forward 5'-
rArGrArUrArUrUrArGrArArArGrGrCrUrCrUrArUrUrCrCAA-3'  
Reverse  5'-
rUrUrGrGrArArUrArGrArGrCrCrUrUrUrCrUrArArUrArUrCrUrGrG-3'  
NC1 
Control   
Forward5'- 
rCrUrUrCrCrUrCrUrCrUrUrUrCrUrCrUrCrCrCrUrUrGrUGA-3'  
Reverse  5'-
rUrCrArCrArArGrGrGrArGrArGrArArArGrArGrArGrGrArArGrGrA-3'     
 NC5 
Control 
Forward 5'- 
rCrArUrArUrUrGrCrGrCrGrUrArUrArGrUrCrGrCrGrUrUAG -3' 
Reverse  5'- 
rCrUrArArCrGrCrGrArCrUrArUrArCrGrCrGrCrArArUrArUrGrGrU-3' 
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Flag-PTGER4 Plasmid 
One Shot chemically competent TOP10 E.coli cells (Invitrogen, UK)) were transformed with   
Flag-PTGER4 (Integrated DNA technologies, Leuven, Belgium) plasmid DNA (OmicsLinkTM 
expression clone EX-Q0086-M11; GeneCopoeia, Rockville, USA) was obtained and propagated 
with Carbenicillin-selective (100 mg/ml) agar plates and Luria-bertani broth (LB).  Plasmid 
DNA was prepared from the cultures using an EndoFree Plasmid Maxi kit (Qiagen, UK). The 
sequence of the Flag-PTGER4 plasmid confirmed by automated DNA sequencing (GATC 
Biotech, Cologne, Germany). 
 
Creation of empty vector control DNA for transfection 
The Flag-PTGER4 was provided in a pReceiver-M11 expression vector. An empty expression 
vector transfection control DNA was needed for this study. This was created from the Flag-
PTGER4 plasmid DNA using site-directed mutagenesis and restriction digestion to obtain a 
pReceiver-M11 plasmid DNA. The plasmid DNA was purified using an EndoFree Plasmid Maxi 
kit (Qiagen, Manchester, UK). The sequence of the pReceiver-M11 plasmid was confirmed by 
automated DNA sequencing. 
 
 Gene expression analysis   
To ensure good reproducibility and reliable data, the qRT-PCR assays were conducted using 
practices laid out in the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines [7].  
 
Cell harvesting and total RNA isolation 
Confluent monocytic cells or THP-1 cells (2 x 106) were placed in 6-well plates and incubated 
with the different treatments to give a final volume of 2 ml. After the incubation period, total 
RNA was isolated from cells using the Sigma Aldrich’s GenElute™ Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, Dorset, UK) following the manufacturer’s instructions. On-
column DNase digestion with the RNase-Free DNase Set (Sigma-Aldrich, Dorset, UK) was used 
to reduce potential carryover genomic DNA contamination. RNA concentration was then 
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measured using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Paisley, UK). 
All of the extracted RNA samples used for PCR had A260/230 and A260/280 purity ratios of around 
2.0.  
 
cDNA synthesis (Reverse Transcription (RT)) 
To quantify the mRNA transcripts of target genes by PCR, total RNA was reverse-transcribed to 
complementary DNA (cDNA) using a Tetro cDNA Synthesis Kit (Bioline, London, UK) 
following the manufacturer’s manual. Total RNAs were normalised to 1 µg per synthesis and 
oligo-dT used to prime the synthesis reaction. The reactions were incubated for 30 min at 42°C, 
and the reaction inactivated by heating to 85°C for 5 min. All these samples were labelled as 
(RT+). The resulting cDNA was then used as the DNA template for quantitative real-time PCR 
for gene expression analysis. To check for the presence of any remaining contaminating genomic 
DNA, an additional reaction tube, labelled (RT-) was prepared in parallel for each RNA samples 
to be used as negative controls in the PCR assays. These samples (RT-) contained all of the 
cDNA synthesis components and total RNA except for the Tetro reverse transcriptase.  
 
Reverse-Transcribed Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) 
RT-qPCR primers were designed against their human mRNA targets and synthesised by 
Integrated DNA Technologies (Leuven, Belgium) or Eurofins MWG Operon (B2M, ACTB, 
HPRT1; Ebersberg, Germany). Their primers sequenced and product sizes are shown in Table 2.  
The RT-qPCR assay was performed by placing the samples in  fast reaction PCRMicroAmp 
tubes (Applied Biosystems, Paisley, UK). The PCR reactions were carried out in 20ul volumes 
containing 19 µl of PCR master mix and 1µl of each template cDNA sample in MicroAmpTM 
Fast Reaction PCR tubes (Applied Biosystems, Paisley, UK). The PCR master mix (1x) 
contained 1 µl of Primer Forward (10 pmol/µl), 1 µl of Primer Reverse (10 pmol/µl), 10 µl of 
Applied Biosystems SYBR® Select Master Mix (Life Technologies, Paisley) and 7 µl RNase-free 
water. Three technical and biological replicates were conducted for each assay. Thermal cycling 
using the SYBR Select Standard Cycling Mode with a combined Anneal and Extend temperature 
of 60°C over 40 cycles and detection was performed on an Applied Biosystems StepOne Plus 
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real-time PCR system. The gene expression levels, represented by the cycle threshold (Ct) 
values, were obtained for each of the reactions. Since this reaction was a SYBR Green-based 
chemistry, a melt–curve analysis was required to follow the amplification.  This was to ensure 
that the PCR reaction only produced a single amplicon and not off-target, multiple products such 
as primer dimers or misprimes which may compromise the gene expression quantification.  
 
∆∆Ct Relative Quantification  
The quantification method selected to validate PCR results was the relative quantification (∆∆Ct) 
method [8]. This method normalises Ct values of the target gene to Ct values of the endogenous 
reference gene in order to demonstrate the fold changes (2-∆∆Ct) in gene expression among control 
and treated samples.  A number of candidate reference genes (PPIB, TBP, GAPDH, RPL37A, 
B2M, ACTB and HPRT1) were screened for their stability and suitability as normalisers using 
RefFinder [9]. 
 
Primer 
Name 
Sequence 
PCR Product 
Size (bp) 
PTGER1  
Forward:  5’- CATGGTGGTGTCGTGCATC -3’ 
Reverse:  5’- TGTACACCCAAGGGTCCAG -3’ 
149 
PTGER2  
 
Forward: 5’- CCTCATTCTCCTGGCTATCATG-3’ 
Reverse:  5’- CTTTCGGGAAGAGGTTTCATTC-3’ 
94 
PTGER3  
 
Forward: 5’- AACTATGCATCCAGCTCCAC -3’ 
Reverse:  5- CAGTTGCCCTCTGTATCTGAG -3’ 
144 
PTGER4  
 
Forward: 5’- ATCTTACTCATTGCCACCTCC-3’ 
Reverse:  5’- TGACTTCTCGCTCCAAACTTG-3’ 
106 
 12 
PPIB 
 
Forward:  5’- ACCTACGAATTGGAGATGAAGATG 
-3’ 
Reverse:  5’- GTCCTTGATTACACGATGGAATTTG 
-3’ 
152 
TBP 
 
Forward:  5’- CTGGTTTGCCAAGAAGAAAGTG -3’ 
Reverse:  5’- GGTCAGTCCAGTGCCATAAG -3’ 
145 
GAPDH 
 
Forward:  5’- ACATCGCTCAGACACCATG-3’ 
Reverse:  5’- TGTAGTTGAGGTCAATGAAGGG-3’ 
143 
RPL37A 
 
Forward:  5’- TGCATGAAGACAGTGGCTG -3’ 
Reverse:  5’- CCAGTGATGTCTCAAAGAGTAGAG 
-3’ 
132 
     
Flag-   
PTGER4 
 
Forward:  5’- AAAGCAGGCTTGGAAGGAGTTCG -
3’ 
Reverse:  5’- CCACGATGGCCACCAGGTTG -3’ 
 
148 
      
B2M 
(Eurofins 
MWG 
Operon, 
Ebersberg/ 
Germany) 
Forward:  5’- 
AGATGAGTATGCCTGCCGTGTGAAC-3’ 
Reverse:  5’- CAAATGCGGCATCTTCAAACCTC-3’ 
 
163 
 Forward:  5’- ATTGCCGACAGGATGCAGAA-3’ 150 
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ACTB 
(Eurofins 
MWG 
Operon, 
Ebersberg/ 
Germany) 
Reverse:  5’- GCTGATCCACATCTGCTGGAA-3’ 
 
 
HPRT1 
(Eurofins 
MWG 
Operon, 
Ebersberg/ 
Germany) 
Forward:  5’- CCCTGGCGTCGTGATTAGTGATG-3’ 
Reverse:  5’- CGAGCAAGACGTTCAGTCCTGTCC-
3’ 
119 
 
Table 2. Nucleotide sequences of the primers used for the analysis of gene expression by RT-
qPCR). 
 
Statistical analysis of PCR data 
All data was analysed statistically using GraphPad Prism Version 5.0 (GraphPad Software Inc., 
California, USA). In all experiments values were mean ± s.d. for three separate observations. 
ANOVA tests were used to ascertain a change with P < 0.05 regarded as a significant change. 
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RESULTS 
Effect of LPS on TNF- production in whole blood, peripheral blood monocytes and THP-1 
cells. 
LPS induced a concentration-dependent increase in TNF- production in whole blood 
incubations, monocytes and THP-1 cells. The maximal increases in TNF- production occurred 
with LPS concentrations between 10 µg/ml – 100 µg/ml in all 3 preparations.  The EC50 
concentrations of LPS for whole blood incubations, monocytes and THP-1 cells were 2.9 µg/ 
ml, 1.9 µg/ ml and 1.2 µg/ ml respectively.  In all subsequent experiments LPS was used at a 
close-to-EC50 LPS concentration of 1 µg/ml to induce TNF- production.  
 
Effect of PGE2 and it’s analogues on TNF-, IL-10 and IL-1production in response to 
LPS. 
The ability of PGE2 and the various EP receptor-selective agonists of PGE2 to modulate TNF- 
production in the different cell systems in response to stimulation with LPS were compared. 
 
Cells or blood were incubated with PGE2 or analogues in the presence or absence of LPS 
(1µg/ml) and TNF- levels in cell supernatants or plasma were measured by ELISA.   
 
The LPS-induced elevation in TNF- levels in blood, normal monocytes and THP-1 cells were 
suppressed in a concentration-dependent manner in the presence of either, PGE2, butaprost 
(EP2-selective) or L-902,688 (EP4-selective). Table 3 shows the IC50 values calculated from the 
concentration-response curve data.  All 3 agonists produced a similar suppressive response on 
TNF-α production.  In general PGE2 showed a lower IC50 than butaprost in all 3 preparations. In 
THP-1 cells the IC50 was in the order of 2-fold lower for L-902,688 than PGE2 but 
approximately 13-fold higher in blood (table 3). 
 
The actions of agonists of all 4 EP receptors on the LPS-induced elevation in TNF- levels were 
directly compared. The following selective EP-receptor agonists were used (all at 1 µM); 
sulprostone (EP1/EP3), L-902,688 (EP4) and butaprost (EP2) and compared directly to PGE2. 
Incubation with either L-902,688 or butaprost resulted in a decrease in the LPS-stimulated 
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elevation of TNF- levels. However, there was no effect of sulprostone on LPS-stimulated 
TNF- (Fig. 1).  
 
The effects of L-902,688  and butaprost were also studied on the LPS-stimulated production of 
both IL-10 and IL-1. Butaprost was able to suppress LPS-stimulated IL-1 and IL-10 
production in a concentration-dependent manner (Fig. 2).  Similarly, L-902,688 also inhibited 
LPS-stimulated IL-1 production in a concentration-dependent manner, however, there was 
little effect on LPS-stimulated IL-10 production (Fig. 2) with a small suppression at the highest 
concentration used (10 µM). 
Expression of mRNA for PTGER2 and PTGER4 in monocytic cells. 
 The expression of the EP4 receptor (PTGER4) gene is shown in Fig. 3. THP-1 cells were 
incubated and processed as described previously. Incubation of THP-1 cells with LPS resulted 
in an up-regulation of PTGER4 mRNA. PGE2 induced a significant reduction in this high level 
of receptor expression (fold stimulation reduced from 2.8 ± 0.6 to 1.3 ± 0.1, p<0.0001).  
 
In a separate experiment, to determine potential regulation of  PTGER4 by the EP4 receptor, 
cells were incubated with the EP4 agonist L-902,688. L-902, 688 also decreased the expression 
of PTGER4 in response to LPS (the fold stimulation decreased from 7.2 ± 0.6 to 0.7 ± 0.1, 
p<0.0001).  However, butaprost did not affect the expression of PTGER2 in LPS-stimulated 
THP-1 cells. The expression level in response to LPS alone and the expression level with 
butaprost (fold stimulation in response to LPS was 20.0 ± 3.5-fold and 20.0 ± 2.1 in the 
presence of butaprost). 
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Cross regulation of PTGER2 and PTGER4 by EP2R and EP4R agonists 
PTGER2 expression was also evaluated in response to the EP4 agonist L-902, 688 (Fig. 3). LPS 
stimulation resulted in an increase in PTGER2 expression compared to control. A 
downregulation (p<0.0001) of PTGER2 by PGE2 was observed. This reduction in PTGER2 
mRNA (in response to LPS) was comparable to the suppression (P<0.0001) by L-902, 688 (Fig. 
3). 
Having established that L-902, 688 reduced both PTGER2 and PTGER4 expression, conversely 
it was decided to ascertain the effect of butaprost (EP2 agonist) on the expression of PTGER4. 
Although PGE2 was able to down-regulate PTGER4 expression (P<0.0001) after LPS 
stimulation butaprost did not significantly reduce the expression of PTGER4 (Fig. 3).  
 
 
The effect of PTGER4 siRNA on TNF-α production in THP-1 cells 
Having established that the expression of PTGER4 could be downregulated only by EP4R 
agonists (PGE2and L-902, 688) it was decided to ascertain whether this was merely at the level 
of gene regulation or whether this also has actual functional consequences. This was achieved 
by using siRNA directed toward the PTGER4 gene and measuring TNF-, IL-1 and IL-10 
production in THP-1 cells. 
 
The production of TNF- was determined during different time points (0h, 6h, 24h and 48h) 
each compared to empty vector at the appropriate time points, following transfection with 
siRNA (Fig. 4).  0h represented TNF- production immediately before transfection of THP-1 
cells with siRNA. At this time point (0h), in response to LPS, the TNF- level increased 
compared to control (empty vector). However, LPS in the presence of PGE2 decreased TNF- 
production. After 6h siRNA post-transfection, there was no clear difference in TNF- 
production compared to 0h (before siRNA transfection). At 24h of stimulation, in response to 
LPS, there was an increase in the TNF- level compared to non-stimulated cells (0h), while 
TNF- production did not change in response to LPS/ PGE2. After 48h of siRNA transfection, 
the TNF- level was higher than earlier time points in response to both LPS and LPS/ PGE2,  
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The levels may have increased further but later time points were not studied. TNF- production 
increased significantly compared to cells before transfection (Fig. 4). Using a negative control 
(random siRNA), there was also a small increase in TNF- levels with a different time course 
but it was not as large an increase as occurred with the positive control. The effect of siRNA 
(directed toward the PTGER4 gene) was also evaluated on both IL-1 and IL-10 production 
following transfection for 48h.  All incubations included either control siRNA duplexes or 
siRNA toward the PTGER4 gene. As previously observed for TNF- production, LPS increased 
the production of both IL-10 and IL-1 and in both cases in the presence of PGE2, LPS-
stimulated IL-10 and IL-1 levels were lower.  PTGER4 siRNA was able to reverse the 
inhibitory actions of PGE2 on LPS-stimulated IL-1 production, however, there was no effect of 
on LPS-stimulated IL-10 levels (Fig. 5). This implies that PTGER4 gene is important in the 
functional suppression of IL-1 and TNF- production by PGE2 but not the suppression of IL-
10.  
 
 
The effect of siRNA on PTGER4 expression in THP-1 cells 
The actions of siRNA on PTGER4 mRNA were also determined to confirm effects at the level 
of expression. A series of experiments were carried out to determine the time course of the 
actions of siRNA on PTGER4 expression. PTGER4 expression was studied between 3 hours 
and 48 hours following transfection with 100 nM siRNA. Figure 6 shows transfection of THP-1 
cells with siRNA for 3 hours in the presence of LPS (1 g/ml). At this time point, there was no 
knockdown observed in PTGER4 expression using siRNA compared to non-transfected cells, 
Similarly after 6 hours and 12 hours post-transfection, siRNA did not induced any significant 
change in PTGER4 expression compared to cells in the presence of LPS alone (untransfected 
cells).  At 24 hours post-transfection a substantial knockdown of PTGER4 expression was 
observed in LPS-stimulated cells (P <0.001). A similar effect was observed at 48h post-
transfection, with a larger reduction in PTGER4 expression (Fig. 6). 
 
Effect of PTGER4 overexpression on LPS-induced TNF production by monocytic cells 
In order to further determine the influence of PTGER4 expression on functional responses a 
converse series of experiments to those using siRNA were carried out. The overexpression of 
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PTGER4 was evaluated on the production of TNF-α by transfecting THP-1 cells with exogenous 
PTGER4 plasmids (Flag-EP4 and empty-vector - 1904ng/μl) for 24h in LPS-stimulated cells. 
LPS stimulation resulted in TNF-α levels which were significantly lower in cells transfected 
with the PTGER4 exogenous plasmid compared to untransfected cells (P<0.01). The empty-
vector, (used as a control without a PTGER4 construct) did not have any significant effect on 
TNF-α production in response to LPS.  
 
A series of experiments were performed to ascertain the time course of the actions of exogenous 
PTGER4 overexpression (plasmid) on TNF-α production in THP-1 cells. The production of 
TNF-α was studied between 6 hours and 24 hours (Fig. 7) following transfection with PTGER4 
plasmid in comparison to untransfected cells (0h).  Untransfected cells (0h) produced a high 
level of TNF-α in response to LPS. PGE2 suppressed this elevated level. After 6h transfection 
with plasmid, there was a significant decrease in TNF-α production in response to LPS 
compared to untransfected cells (P < 0.01).  In addition, PGE2 was able to induce a greater 
decrease in TNF-α level in LPS-stimulated cells (Fig. 7) compared to the corresponding 
untransfected cells (P < 0.01). At 24h post-transfection with PTGER4 plasmid, the inhibition by  
PGE2 of LPS-stimulated TNF-α levels was reduced to that very close to cells incubated without 
LPS. 
 
 
The effect of PGE2 and and various agents on cell viability   
In order to exclude the possibility that the suppression of LPS-induced TNF- production may 
be indirectly related to cell viability, the effect of the various compound/ reagents on THP-1 cell 
viability was assessed using 2 different methods, one estimating non-viable cells (Trypan blue 
exclusion) and the other measuring total viable cells (MTT assay). The total number of viable 
cells in control incubations was adjusted to 100 % ± 2.5% and the viable cells in the presence of  
PGE2, Butaprost, Sulprostone and L-902, 688 (all at 1 µM) which were compared to control 
levels indicated 103 ± 1.5%, 105 ± 0.5%*, 101 ± 2.2% and 100 ± 2.4% respectively (n = 3 ± s.d. 
both P < 0.05 by ANOVA).  The viability of cells (1 x 105 cells) using the MTT method was 
less subjective and was expressed directly as absorbance of the amount of converted dye.  The 
control cells yielded a mean absorbance of 1.213 ± 0.024 and in the presence of PGE2, 
Butaprost, Sulprostone and L-902, 688  the mean absorbances were 1.291 ± 0.125*, 1.411 ± 
0.029*, 1.228 ± 0.035 and 1.214 ± 0.005 respectively (n =3 ± s.d. both P < 0.05 by ANOVA). 
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Both methods indicated that the prostanoid/ agonists appeared to have a mild cytoprotective 
action on THP-cell viability.  
 
The effect of the various reagents used in transfection studies were also assessed for their effects 
on cell viability using the MTT assay and the data are shown in Table 4. Dead cells were 
prepared by briefly boiling viable cells in a water bath for 30s.  
 
Treatment   Viable cells (%) 
Control (untreated cells) 100 ± 1.5% 
siRNA 108 ± 0.05% 
Positive control 103 ± 0.02% 
Negative control 1 100 ± 2.5%  
Negative control 5 110 ± 0.03% 
Hiperfect 100 ± 1.2%  
Dead cells 0 ± 0.001% 
 
Table 4 Effect of transfection reagents on cell viability (MTT assay, n = 4) 
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DISCUSSION 
 
In this study we report that PGE2 is a potent suppressor of LPS-stimulated TNF- production in 
human monocytic cells and that expression of the genes (PTGER1 - 4) for the various PGE2 
receptors (EP1 – EP4) is important in the suppressive response to PGE2 particularly the EP4 
receptor.  
 
PGE2 and its analogues on the suppression of cytokine production 
In the present study we confirmed the suppressive action of PGE2 and various EP receptor 
ligands. Both PGE2 and the EP2R agonist butaprost demonstrated potent suppression of LPS-
stimulated TNF-α production in all 3 preparations used, whole human blood, normal monocytes 
(isolated from peripheral blood) THP-1 cells. The IC50 values for both PGE2 and butaprost 
(table 3) indicate that all 3 preparations respond in a qualitatively identical manner. THP-1 cells, 
a human monocyte cell line, responded to PGE2, butaprost and the EP4R agonist L-902,688 by 
suppressing TNF-α production. Both PGE2 and L-902,688 showed a much lower IC50 for the 
suppression of TNF-α production than butaprost (table 3). This was similar to the comparative 
effects of PGE2 and butaprost in normal monocytes.  Thus, in subsequent studies THP-1 cells 
were used as a plausible surrogate for normal monocyte functions and processes. This was 
necessary as the yield of monocytes from blood is generally very low and highly variable as the 
blood derives from different donors.  THP-1 cells have been shown in many studies to be 
suitable for revealing the molecular processes of monocytes especially those focused on the 
control of inflammatory cytokine production and responses to lipid-derived modulators [1, 10, 
11]. 
 
It is unclear what receptors (EP1 – EP4) are important in suppressing TNF-α production. It is 
well established that both EP2Rs and EP4Rs can result in suppressive action on the basis of 
selective ligands for each receptor.  This was confirmed in the present study where butaprost 
and L-902,688 were comparable to PGE2 in their inhibitory activity in both blood and THP-1 
cells indicating EP2R and EP4R involvement (Fig. 1). In contrast, sulprostone did not have any 
effect on the suppression of LPS-stimulated TNF-α production.  Sulprostone acts non-
selectively via EP1/EP3 receptors [12-14]. This clearly demonstrates that neither EP1 nor EP3 
receptors play any role in controlling pro-inflammatory cytokine production.  
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Butaprost is an EP2-selective agonist and has been shown to supress cytokine levels in a wide 
variety of immune cells such monocytes and NK cells [1, 15]. This is consistent with antagonist 
selectivity, the EP2 antagonist AH6809 can reverse the actions of butaprost and  PGE2  [1] 
specifically TNF-α production. There are many previous studies that agree with this [13, 16-18]. 
This shows the potent suppressive actions on TNF-α production mediated via EP2 receptors as 
butaprost has a high selectivity for the EP2R [19] and has been used extensively in functional 
studies. Similarly, L-902,688 is a highly selective EP4 agonist and has been shown to be >4000-
fold more selective for the EP4R than the other EP receptors [20]. The involvement of the EP4 
receptor in cytokine inhibition has been evaluated previously [1, 21] and the data obtained here 
indicate an important role. Thus, butaprost and L-902,688 were subsequently used to ascertain 
the receptor-selective modulation of EP receptor gene expression, specifically expression of 
PTGER2 and PTGER4 genes.  
 
Expression of EP receptors in THP-1 cells 
Each EP receptor has a unique expression pattern and is linked to different signalling pathways 
[6]. EP4 receptor mRNA is abundant in LPS-stimulated human monocytes [22] which implies 
that the EP4 receptor has a role in cytokine modulation. For example, in chronic inflammation, 
the expression of mRNA for the EP4 receptor is up-regulated, whereas there is a low expression 
of PTGER2 and no detectable expression of   PTGER1 or PTGER3 [22]. An earlier study also 
agreed with this and showed that there is an increased expression of EP4 and EP2 receptor 
mRNA, while the mRNA levels mRNA for EP1 and EP3 receptors are barely detectable [23]. 
This is in agreement with the present study which shows that LPS induced an increase in the 
expression of both EP4 (PTGER4) and EP2 receptors (PTGER2) receptors in THP-1 cells:, 
whereas EP1 and EP3 receptors (PTGER1, PTGER3) were below the level of detection. In this 
study the expression of PTGER4 and PTGER2 could be downregulated by L-902,688 but 
butaprost only affected PTGER2 expression implying that expression is controlled by PGE2 
primarily via the EP4 receptor. Additional evidence for this has been reported where the EP4 
agonist (ONO-AE1-329) inhibited TNF-α production in EP2-receptor-deficient cells. However, 
the effect of EP2 agonist (ONO-AE1-259) on TNF-α in EP4-deficient cells was not potent as the 
EP4 agonist [24]. Therefore, this may indicate that the EP4 receptor is the major anti-
inflammatory regulator. An important observation in the present study was the effect of 
PTGER4 siRNA on the LPS-stimulated production of TNF- and IL-1 where the PGE2-
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induced suppression of both was reversed, however, this was not the case for the anti-
inflammatory cytokine IL-10 (Figs. 4 and 5). This implies that the EP4 receptor may 
downregulate pro-inflammatory cytokines whilst simultanously sparing anti-inflammatory 
mechanisms. A genetic deletion or significant mutation of the PTGER4 gene especially in 
monocytes may result in a substantial loss of suppressive activity on pro-inflammatory cytokine 
levels. In the case of EP4 receptor deficiency PGE2 fails to have any effect on LPS-stimulated 
TNF-α induction [25]. This observation is strongly in agreement with the current data (Fig. 4) 
which also demonstrated that silencing PTGER4 expression using siRNA resulted in increased 
TNF-α production indicating the functional failure of suppression in response to exogenous 
PGE2. This was confirmed by overexpressing PTGER4 using an exogenous plasmid, which 
amplified the inhibitory actions of PGE2 on TNF-α production (Fig. 7). 
 
In conclusion, EP2R and EP4R ligands can both result in the inhibition of pro-inflammatory 
cytokine production. However, with respect to gene expression for the receptors, only the EP4 
ligand was able to modulate the expression of both receptors.  The functional significance of the 
modulation of expression of PTGER4 was confirmed by both knockdown of the gene using 
siRNA and overexpression using a PTGER4 plasmid. This clearly showed that the changes in 
expression are not merely at the level of mRNA but actually have functional consequences.  
This also indicates that modulation of pro-inflammatory production by PGE2 is determined by 
dynamic changes in receptor-expression-coupling and is not merely determined by a static level 
of receptors present at any particular time. The relative lack of effect on IL-10 production by 
EP4R processes is an important advantage in the development of anti-inflammatory targets. This 
may have consequences not only for the development of therapeutic strategies but potentially 
also for understanding the underlying mechanisms of pathology of some inflammatory diseases 
which may involve a failure of EP receptor-mediated control. 
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Figures and Table Legends 
 
Table 3. 
IC50 values for the suppressive actions of PGE2, butaprost and L-902,688 on LPS-
stimulated TNF-α production.  Blood or cells were incubated with varying concentrations of 
the agonists (0.01 – 10 µM) in the absence or presence of LPS (1 µg/ml) and the IC50 values (all 
nM) from the corresponding data was statistically calculated. 
 
Fig. 1.  Direct comparison of EP receptor ligands on LPS-stimulated TNF-α production. 
Blood (A) or THP-1 cells (B) were incubated in the absence or presence of LPS (10 µg/ ml) 
with the various EP receptor agonists (all at 1 µM); PGE2, sulprostone (sulp), L-902,688 (L-9) 
or butaprost (but) for 22h at 37 °C, 5 % CO2 and 100 % humidity, after which the plasma or cell 
supernatants were collected by centrifugation.  The level of TNF- in samples was measured by 
ELISA. Values are the means of n = 3 ± s.d.  *P < 0.01 versus LPS alone. 
 
Fig. 2.  The effect of butaprost and  L-902,688 on LPS-stimulated IL-10 and IL-1 
production. 
THP-1 cells were incubated in the absence (0 µM) or presence of various concentrations of 
either butaprost (circles) or L-902,688 (squares) either alone (open symbols) or together with 
LPS (10 µg/ml – filled symbols). The open triangles indicated THP-1 cells incubated alone 
(control). Cells were incubated for 22h at 37 °C, 5 % CO2 and 100 % humidity, after which the 
cytokine levels in cell supernatants were measured by ELISA. Values are the means of n = 3 ± 
s.d.  *P < 0.01 versus LPS alone and #P < 0.01 versus control incubations for each cytokine. 
 
 
Fig. 3.  Expression of PTGER2 and PTGER4 in response to various agonists. THP-1 cells 
were placed into 6-well plates after which LPS (10 µg/ ml), PGE2 (1M), L-902, 688 (1M) and 
culture medium (control) were added and cells incubated for 22h. Total RNA was prepared from 
the cells. After reverse transcription, quantitative PCR analysis was performed on the cDNA 
using selected primers for either A. PTGER4 or B. PTGER2 as describe previously. Relative 
expression levels of mRNA transcripts were normalized to the reference gene PPIB using the 
delta-delta Ct method as described previously (methods section). Values are the means of n = 3 
± s.d. ***P <0.0001 versus LPS alone.  
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Fig. 4.  Time course of the effect of PTGER4 siRNA on TNF-α production in THP-1 cells. 
Cells were placed into 6-well plates after which LPS (10 g/ml), PGE2 (1M) and culture 
medium (control) were added and cells were transfected with siRNA duplexes using Hiperfect. 
The plates were incubated for various times at 37 °C, 5 % CO2 and 100 % humidity, after which 
the level of TNF- in culture medium was measured by ELISA. Values are the means of n = 3 ± 
s.d. *P < 0.01 versus LPS for untransfected (0h) cells and #P< 0.01 versus LPS alone. 
 
Fig. 5.  The effect of PTGER4 siRNA on LPS-stimulated IL-10 and IL-1 production in THP-1 cells. 
Cells were incubated with either LPS (10 g/ml), PGE2 (1M), culture medium (control) or a combination 
thereof. All cells were transfected with either control siRNA duplexes or siRNA toward PTGER4 
(indicated by siRG4 on Figs). The plates were incubated for 48h at 37 °C, 5 % CO2 and 100 % humidity, 
after which the levels of IL-10 (A) and IL-1 (B) in the cell supernatants was measured by ELISA. 
Values are the means of n = 3 ± s.d. *P < 0.01 versus LPS + PGE2 with control siRNA, 
#P< 0.01 versus 
cells alone (both containing control siRNA) and §P < 0.01 versus LPS alone. 
 
 
Fig. 6.  The effect of siRNA toward PTGER4 on gene expression. THP-1 cells were placed 
into 6-well plates after which LPS (10 g/ml), PGE2 (1M) and culture medium (control) were 
added and cells were transfected with siRNAs using Hiperfect. The plates were incubated for 
the indicated periods of time after which total RNA was prepared from the cells. After reverse 
transcription, quantitative PCR analysis was performed on the cDNA using primers to detect 
PTGER4 (see methods section) Relative expression levels of PTGER4 mRNA transcripts were 
normalized to the reference gene PPIB using the delta-delta Ct method as described previously. 
Values are the means of n = 3 ± s.d. **P < 0.001 versus untransfected cells. 
 
 
Fig. 7.  The effect of PTGER4 overexpression on TNF-α production in THP-1 cells. Cells 
were incubated in 6-well plates with PTGER4 plasmid and empty-vector plasmid in the absence 
or presence of LPS (10μg/ml) or PGE2 (1M). The plates were incubated for various times at 37 
°C, 5 % CO2 and 100 % humidity, following transfection after which the level of TNF-α in 
culture medium was measured by ELISA. Values are the means of n = 3 ± s.d. *P < 0.01 versus 
LPS alone and #P < 0.05 versus untransfected cells (0h). 
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Table 3 
Agonist/ cells blood monocytes THP-1 cells 
PGE2 3.8 13.3 35.4 
butaprost 55.4 330.3 200.4 
L-902,688 51.6 n.d. 16.0 
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